- Home
- News
- Treatment & Care
- HIV Worldwide
- Living with HIV
- Preventing HIV
- Organisations
- HIV Basics
- About Us
-
HATIP #1, 13th March 2003
-
HATIP #2, 27th March 2003
-
HATIP #3, 10th April 2003
- HATIP #4, 24 April 2003
-
HATIP #5, 8 May 2003
-
HATIP #6, 23 May 2003
-
HATIP #7, 12 June 2003
-
HATIP #8, 26 June 2003
- HATIP #9, 10th July 2003
-
HATIP #10, 24 July 2003
-
HATIP #11, 7 August 2003
- HATIP #12, 28 August 2003
-
HATIP #13, 11 September 2003
-
HATIP #14, 2 October 2003
-
HATIP #15, 9 October 2003
- HATIP #16, 23 October 2003
- HATIP #17 , November 6 2003
- HATIP #18 24 November 2003
- HATIP #19, 4 December 2003
- HATIP #20, 19 December 2003
feedback
Give us your views on our work
HATIP #9, 10th July 2003
News headlines
A selection of news stories which have appeared since 26 June 2003
Brazilian study finds reduced bone protein levels in people with HIV
HIV-positive patients have lower levels of a protein associated with bone density according to a small Brazilian study published in the July 4th edition of AIDS.
HIV Resistance Workshop 2003: resistance in non-B HIV subtypes
Two years ago at the HIV Resistance Workshop Deenan Pillay from University College London noted in his overview presentation that only 4% of the meeting abstracts addressed issues related to non-B viral subtypes an almost inverse proportion he observed, to the worlds population affected by non-B virus. This year, Dr Pillay commended the meeting on extending this level of interest to 12%. Hopefully, future plans for surveillance and investments in research in least developed countries will teach us more about the evolution of resistance in non-B subtypes.
HAART patients have increased risk of heart disease say French
HIV-positive individuals taking a HAART combination including a protease inhibitor (PI )have a slight, but significant, increased risk of long-term coronary heart disease compared to the general population, according to a French study published in the online edition of Clinical Infectious Diseases.
High-dose pulsed therapy - the future for structured treatment breaks?
A study conducted before the availability of HAART, but only recently published in the July 1st edition of the Journal of Acquired Immune Deficiency Syndromes, has found that using pulses of high dose d4T monotherapy can achieve a significant reduction in HIV viral load and transient increases in CD4 cell count in HIV-positive individuals who have been extensively pre-treated with AZT.
HAART causes asymptomatic lactate increase in third of HIV-positive children
A third of HAART-treated children had elevated lactic acid levels in a US study published in the July 4th edition of AIDS. Increased lactic acid levels did not cause symptoms, and were associated with an undetectable viral load, suggesting to the investigators that measuring lactic acid levels could be a useful measure of adherence in children.
About HATIP
A regular electronic newsletter for health care workers and community-based organisations on HIV treatment in resource-limited settings.
Its publication is supported by the UK government's Department for International Development (DfID), the Diana, Princess of Wales Memorial Fund and the Stop TB Department of the World Health Organization.
Other supporters include Positive Action GlaxoSmithKline (founding sponsor); Abbott Fund; Abbott Molecular; Cavidi; Elton John AIDS Foundation; Merck & Co., Inc.; Pfizer Ltd; F Hoffmann La Roche; Schering Plough; and Tibotec, a division of Janssen Cilag.
latest aidsmap news
- HIV/TB epidemic in Eastern Europe a 'public health disaster'
- Low bone mineral density common in HIV-positive men
- Circumcision may protect HIV-negative gay men from syphilis
- HIV 'exposure' from bite forms basis for terrorism charge in US case
- First hint of a hepatitis C vaccine?
- Pregnancy, not nevirapine cause of liver toxicities in HIV-positive women
- Surviving to die of something else: AIDS is a rare cause of death in old people with HIV
- New EACS guidelines address co-morbidities and diseases of age
- Small case series looks at etravirine during pregnancy
- Protease inhibitor monotherapy as a maintenance regimen: are we edging towards acceptance?